Regulation 40 Amendment of regulation 45E (criteria of broker's registration)I1
United Kingdom
M1In regulation 45E(3) —
for sub-paragraph (b)(i) substitute—
“(i)ordered by—
(aa)in the case of a broker in Great Britain, the licensing authority or by an appropriate authority responsible for the licensing of medicinal products in an approved country for import, or
(bb)in the case of a broker in Northern Ireland, the licensing authority or by the competent authority of any EEA State, or”;
in sub-paragraph (d)(iii), before “the batch number” insert “where the sale or supply of the medicinal product is in Northern Ireland,”.
Annotations
Textual amendments
- F1
Reg. 40(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 29(a)
- F2
Reg. 40(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 29(b)
Marginal citations
- M1
Regulation 45E was inserted by S.I. 2013/1855.
Commencement
- I1
Reg. 40 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1